Kopran Peer Comparison

NSE: KOPRAN | BSE: 524280

₹201.76

₹9.04 (4.69%)

As on 28-Aug-2026IST

Market cap

₹972 Cr

Revenue (TTM)

₹700 Cr

P/E Ratio

38.9

P/B Ratio

1.8

Div. Yield

1.5 %

Edit

	Kopran	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	972	32,104	29,892	29,103	26,871
Revenue (₹ Cr)	700	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	24.98	414.00	288.22	-371.81	387.35
Net Margin (%)	3.56	11.23	14.79	-3.93	26.01
RoE (%)	4.84	8.38	29.77	-3.85	25.18
Price to Earnings	38.89	78.49	103.71	--	69.57
Price-To-Book	1.81	6.38	22.27	3.64	15.55

Income Statement (₹ Cr)

	Kopran	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	681.42	3,373.00	1,753.96	8,869.08	1,006.88
Total Income	681.77	3,510.00	1,762.66	9,111.51	1,023.80
Total Expenditure	619.47	2,747.00	1,354.69	7,976.59	774.80
EBITDA	61.95	626.00	399.26	892.49	232.07
Depreciation	17.47	227.00	45.26	831.24	26.62
EBIT	44.48	399.00	354.00	61.25	205.45
Interest	10.47	213.00	42.17	340.80	6.22
Other Income	0.35	137.00	8.70	242.43	16.93
Exceptional Items	--	-85.00	--	-196.14	--
Profit before Tax	34.36	238.00	320.53	-176.06	216.16
Provision for Tax	8.63	39.00	73.80	149.88	55.75
Profit after Tax	25.73	199.00	246.74	-325.94	160.42

	Kopran	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	530.28	4,940.00	1,288.82	8,162.62	1,309.63
Minority Interest	--	341.00	0.00	--	10.45
Non-Current Liabilities	31.90	1,235.00	189.02	4,529.41	26.93
Current Liabilities	346.18	1,622.00	835.87	4,874.74	202.25
Total Liabilities	908.36	8,578.00	2,326.71	17,723.32	1,549.26

	Kopran	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	385.19	5,441.00	631.90	10,258.66	757.63
Current Assets	523.18	2,606.00	1,681.81	7,308.11	791.64
Total Assets	908.36	8,578.00	2,326.71	17,723.32	1,549.26
Total Debt*	152.69	2,125.00	259.37	5,495.48	8.18
Net Current Assets	177.00	984.00	845.94	2,433.37	589.39
Contingent Liabilities	18.95	768.26	19.09	95.72	15.38

	Kopran	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	66.75	390.00	205.05	1,652.60	118.34
Cash Flow from Investing Activities	-64.60	-241.00	-409.72	-826.03	-223.94
Cash from Financing Activities	-20.94	-54.00	283.07	-38.98	261.12
Net Cash Inflow / Outflow	-18.79	95.00	78.39	787.59	155.52

	Kopran	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	6.65	6.79	29.22	1.24	20.14
ROE (%)	4.92	4.29	27.84	-4.04	16.19
ROA (%)	2.94	2.53	13.11	-1.98	12.13
EBIT Margin (%)	9.14	22.62	23.26	12.80	24.73
Net Margin (%)	3.77	5.67	14.00	-3.58	15.67
Cash Profit Margin (%)	6.34	10.98	7.71	4.80	18.58

	Kopran	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	8.23	11.99	36.57	-3.08	40.34
EBIT Growth (%)	-18.97	67.69	52.29	-28.15	83.12
Net Profit Growth (%)	-33.26	449.12	83.64	-457.66	229.35
EPS Growth (%)	-33.25	553.20	71.44	-456.91	67.16
Book Value Growth (%)	2.36	13.47	144.31	0.33	94.96

	Kopran	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	20.25	89.54	51.69	0.00	62.97
Price / Book Value	0.99	3.87	10.14	2.24	15.26
Dividend Yield (%)	2.78	0.00	0.19	0.00	0.06
EV/EBITDA	10.70	27.45	31.05	19.72	79.31
Market Cap (₹ Cr)	521.02	19,071.62	12,753.19	18,108.89	19,988.69

	Kopran	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	0.29	0.43	0.21	0.68	0.01
Short term debt to equity ratio	0.26	0.09	0.05	0.09	0.01
Current Ratio	1.51	1.61	2.01	1.50	3.91
Quick Ratio	1.04	1.06	1.14	0.87	3.02
Interest Coverage	4.28	2.12	8.60	0.48	35.76

	Kopran	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	38.55	17.43	29.00	24.33	28.85
Asset Turnover	0.78	0.49	2.01	0.64	0.76
Receivable days	127.91	58.75	40.13	78.20	90.06
Inventory Days	89.35	75.82	60.29	93.30	61.02
Payable days	122.98	186.21	232.47	226.14	96.06
Cash Conversion Cycle	94.28	-51.64	-132.04	-54.64	55.02

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.